Novel HDACi CS014
HDAC inhibitor CS014 is a new chemical entity with a multi-modal mechanism of action as an epigenetic modulator, under development for Idiopathic Pulmonary Fibrosis (IPF).
Preclinical studies of HDAC inhibitors show that these drugs can reverse fibrosis in models of IPF. Studies also show that these drugs prevent the pathological remodeling of pulmonary vessels that ultimately leads to pulmonary hypertension in many IPF patients. Preclinical studies of CS014 have demonstrated an effect on reversal of fibrosis and a dose-dependent beneficial effect on pathological vascular remodeling in an established model of PAH. Together, these findings indicate that CS014 has the potential to address the underlying pathophysiology behind the development of IPF.
CS014 has demonstrated, in preclinical studies, the ability to regulate platelet activity, local fibrinolysis, and clot stability, helping to prevent thrombosis without increasing the risk of bleeding. This supports CS014's potential to address key unmet needs in IPF patients.
Cereno’s HDAC inhibitor portfolio, capitalizing on the principle of epigenetic modulation, comprises Cereno’s lead drug candidate CS1 and the investigational drug candidate CS014. In March 2019, CS014 was acquired from Emeriti Bio and is being developed in a collaboration between Cereno, Emeriti Bio and University of Michigan.
A first-in-man, Phase I trial of CS014 was initiated in June 2024.